Emodin regulates the autophagy via the miR-371a-5p/PTEN axis to inhibit hepatic malignancy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Liver cancer presents a significant global health challenge.
• Emodin, a natural compound, shows potential in suppressing liver cancer progression.
• Understanding the molecular mechanisms of emodin's action is crucial for therapeutic development.

Purpose of the Study:

• To investigate the molecular mechanisms by which emodin inhibits liver cancer.
• To explore the role of microRNA-371a-5p (miR-371a-5p) and its downstream targets in emodin's anti-cancer effects.
• To elucidate the involvement of cellular autophagy in emodin-mediated liver cancer suppression.

Main Methods:

• MicroRNA sequencing (miRNA-seq) was performed on liver cancer cell lines treated with emodin.
• Functional experiments were conducted to assess the impact of miR-371a-5p modulation on cancer cell proliferation.
• Bioinformatic predictions and Western blotting were used to identify and validate PTEN as a downstream target of miR-371a-5p.
• Autophagy-related protein markers (LC3II and P62) were analyzed to assess autophagic activity.

Main Results:

• Emodin treatment led to the down-regulation of miR-371a-5p expression in liver cancer cell lines.
• Restoring miR-371a-5p levels attenuated the inhibitory effects of emodin on cancer cells.
• PTEN was identified as a direct downstream target of miR-371a-5p.
• Emodin treatment increased the expression of the autophagy marker LC3II and decreased P62, indicating enhanced autophagy.
• The miR-371a-5p/PTEN axis was shown to mediate emodin's regulation of cellular autophagy.

Conclusions:

• Emodin inhibits liver cancer progression, partly through the miR-371a-5p/PTEN signaling pathway.
• This pathway modulates cellular autophagy, contributing to emodin's anti-cancer effects.
• The findings provide a theoretical basis for utilizing traditional Chinese medicine compounds like emodin in clinical oncology for liver cancer treatment.